REFERENCES
- Remington Farmacia, A. R. Gennaro, et al. 19th Ed., Médica Anamericana, Buenos AiresArgentina 1995; 2226
- Helman J. Pharmacotecnia Teórica y Práctica. Continental, Mexico, D.F. 1980; 1139–1143
- Lácer J. M., Gallardo V., Parera A., Ruiz M. A. Formation of Ondansetron Polymorphs. Int. J. Pharm. 1999; 177: 221–229
- Blackwell C. P., Harding S. M. The Clinical Pharmacology of Ondansetron. Eur. J. Cancer Clin. Oncol. 1989; 25(suppl. 1)21–24
- Freeman A. J., et al. Selectivity of 5-HT3 Receptor Antagonist and Anti-emetic Mechanisms of Action. Anti-cancer Drugs 1991; 3: 79–85
- Roita F., Del Favero A. Ondansetron Clinical Pharmacokinetics. Clin. Pharmacokinetics 1995; 29(2)94–108
- Sheldrick G. M. SHELXTL-Plus. Program for the Solution of Crystal Structures. Release 3.4, University of Göttingen, GöttingenGermany 1989
- Hughes J. C., Brown G. J. Soil Sci. 1971; 30: 557–563